BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30982327)

  • 1. Neural activities are unfavorable for the prognosis of ovarian cancer through mRNA expression analysis.
    Yang L; Bie L; Sun L; Yue Y
    Biomark Med; 2019 Jun; 13(8):663-673. PubMed ID: 30982327
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
    Li Y; Li L
    J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer.
    Zheng R; Chen W; Xia W; Zheng J; Zhou Q
    Biomed Res Int; 2020; 2020():7658782. PubMed ID: 33282953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
    Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
    J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Netrin-1 overexpression is predictive of ovarian malignancies.
    Papanastasiou AD; Pampalakis G; Katsaros D; Sotiropoulou G
    Oncotarget; 2011 May; 2(5):363-7. PubMed ID: 21789787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.
    Lu YM; Wang Y; Liu SQ; Zhou MY; Guo YR
    Oncol Rep; 2018 Nov; 40(5):2964-2976. PubMed ID: 30132558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.
    Mandilaras V; Vernon M; Meryet-Figuière M; Karakasis K; Lambert B; Poulain L; Oza A; Denoyelle C; Lheureux S
    Expert Opin Biol Ther; 2017 Aug; 17(8):927-943. PubMed ID: 28641048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis.
    Feng H; Gu ZY; Li Q; Liu QH; Yang XY; Zhang JJ
    J Ovarian Res; 2019 Apr; 12(1):35. PubMed ID: 31010415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
    Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
    Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
    J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
    Chen H; Tian X; Luan Y; Lu H
    Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.
    Hossain MA; Saiful Islam SM; Quinn JMW; Huq F; Moni MA
    J Biomed Inform; 2019 Dec; 100():103313. PubMed ID: 31655274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis.
    Cao T; Pan W; Sun X; Shen H
    J Ovarian Res; 2019 Oct; 12(1):101. PubMed ID: 31656201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling and bioinformatics analyses reveal differential circular RNA expression in ovarian cancer.
    Wang J; Wu A; Yang B; Zhu X; Teng Y; Ai Z
    Gene; 2020 Jan; 724():144150. PubMed ID: 31589961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a five-gene signature as a novel prognostic marker in ovarian cancer.
    Wang R; Ye XH; Zhao XL; Liu JL; Zhang CY
    Neoplasma; 2019 May; 66(3):343-349. PubMed ID: 30569721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A random forest classifier predicts recurrence risk in patients with ovarian cancer.
    Cheng L; Li L; Wang L; Li X; Xing H; Zhou J
    Mol Med Rep; 2018 Sep; 18(3):3289-3297. PubMed ID: 30066910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of ovarian carcinomas and prognostic analysis of outcome.
    Cai SY; Yang T; Chen Y; Wang JW; Li L; Xu MJ
    J Ovarian Res; 2015 Jul; 8():50. PubMed ID: 26228058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression and prognosis of sirtuin family members in ovarian cancer.
    Zeng Z; Huang Y; Li Y; Huang S; Wang J; Tang Y; Jiang Y
    Medicine (Baltimore); 2020 Jun; 99(24):e20685. PubMed ID: 32541517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients.
    Zheng H; Zhang M; Ma S; Yang W; Xie S; Wang Y; Liu Y; Kai J; Ma Q; Lu R; Guo L
    Cancer Med; 2020 Jul; 9(14):5200-5209. PubMed ID: 32441484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.